Importance of HDL Cholesterol as Predictor of Coronary Heart Disease in Jordan Population: The Role of HDL-Subfractions in Reverse Cholesterol Transport

2002 ◽  
Vol 5 (11) ◽  
pp. 1189-1191 ◽  
Author(s):  
Mohammad A. Salahat ◽  
Husni S. Farah ◽  
Yahya S. Al-Degs
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Reverse Cholesterol Transport ◽  
Hdl Cholesterol ◽  
Cholesterol Transport ◽  
Hdl Subfractions

scholarly journals Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes

Diabetologia ◽  
2004 ◽  
Vol 47 (12) ◽  
pp. 2129-2136 ◽  
Author(s):  
M. B. Schulze ◽  
I. Shai ◽  
J. E. Manson ◽  
T. Li ◽  
N. Rifai ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Hdl Cholesterol ◽  
Glycated Haemoglobin

scholarly journals Beyond Statins: Emerging Evidence for HDL-Increasing Therapies and Diet in Treating Cardiovascular Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Sterling Farrer
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Stress Reduction ◽  
Reverse Cholesterol Transport ◽  
Treatment Options ◽  
The United States ◽  
Exercise Stress ◽  
Cholesterol Transport ◽  
Peripheral Tissues ◽  
Positive Effects

Coronary heart disease continues to be the leading cause of death in the United States. Current attempts to treat atherosclerosis and coronary artery disease often involve pharmaceutical and surgical treatments. While these treatments are successful in managing the pain from coronary heart disease, they do little to prevent or stop it. There are a number of clinical strategies that are currently being researched to treat atherosclerosis through HDL-increasing therapies. These clinical studies have shown positive effects through nutritional intervention, exercise, stress reduction, and tobacco and alcohol cessation. These treatment options are explored in greater detail, including their potential to halt and even reverse atherosclerosis. The results from these recent studies and how they relate to the mechanism of reverse cholesterol transport are also critically examined. Reverse cholesterol transport is a multistep process resulting in the net movement of cholesterol from peripheral tissues back to the liver via the plasma. The mechanism of reverse cholesterol transport is also further explored in this review.

scholarly journals The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: A two-step, two-sample Mendelian randomization study

2017 ◽  
Author(s):  
Lin Xu ◽  
Maria Carolina Borges ◽  
Gibran Hemani ◽  
Deborah A Lawlor
Keyword(s):  
Risk Factors ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Research Council ◽  
Mendelian Randomization ◽  
Fasting Glucose ◽  
Causal Effect ◽  
Hdl Cholesterol

AbstractBackgroundThe extent to which effects of BMI on coronary heart disease (CHD) are mediated by gylcaemic and lipid risk factors is unclear.MethodsWe used two-sample Mendelian randomization to determine the causal effect of: (i) BMI on CHD (60,801 cases; 123, 504 controls), type 2 diabetes (T2DM; 34,840 cases; 114,981 controls), fasting glucose (n=46,186), insulin (n=38,238), HbA1c (n=46,368), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C) and triglycerides (n=188,577); (ii) glycaemic and lipids traits on CHD; and (iii) extent to which these traits mediated any effect of BMI on CHD.FindingsOne standard deviation (SD) increase in BMI (~ 4.5kg/m2) increased CHD (odds ratio=1.45 (95% confidence interval (CI): 1.27, 1.66)) and T2DM (1.96 (1.35, 2.83)), and levels of fasting glucose (0.07mmol/l (95%CI 0.03, 0.11)), HbA1c (0.05% (95%CI 0.01, 0.08)), fasting insulin (0.18log pmol/l (95%CI 0.14, 0.22)) and triglycerides (0.20 SD (95%CI 0.14, 0.26)), and lowered levels of HDL-C (−0.23 SD (95%CI −0.32, −0.15)). BMI was not causally related to LDL-C. After accounting for potential pleiotropy, triglycerides, HbA1c and T2DM were causally related to CHD. The BMI-CHD effect reduced from 1.45 to 1.16 (95%CI 0.99, 1.36) and to 1.36 (95%CI 1.19, 1.57) with genetic adjustment for triglycerides or HbA1c respectively, and to 1.09 (95%CI 0.94, 1.27) with adjustment for both.InterpretationIncreased triglyceride levels and poor glycaemic control appear to mediate much of the effect of BMI on CHD.FundingEuropean Research Council (669545), European Union (733206), China Medical Board (CMB_2015/16), Conselho Nacional de Desenvolvimento Científico e Tecnológico and UK Medical Research Council (MC_UU_12013/5).

scholarly journals Role of lipoprotein(a) in the development of coronary heart disease in patients with essential hypertension

2003 ◽  
Vol 22 (4) ◽  
pp. 341-346 ◽  
Author(s):  
Zorica Caparevic ◽  
Nada Kostic ◽  
Sinisa Dimkovic ◽  
Branislava Brkic ◽  
Radojka Cvetkovic
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Essential Hypertension ◽  
Cardiovascular Risk ◽  
Hdl Cholesterol ◽  
Serum Samples ◽  
Hypertensive Patients ◽  
Lipoprotein A ◽  
Fresh Serum

Lipoprotein(a) [Lp(a)] is an important and independent cardiovascular risk factor, but its role in the development of coronary heart disease (CHD) in hypertensives have had conflicting results. In order to study the possible role of Lp(a) in the development of coronary heart disease in hypertensive patients, we evaluated Lp(a) levels in 45 (younger than 50 years) CHD hypertensive patients, 45 patients with essential hypertension with?out CHD and 64 healthy controls. Lp(a) was measured by nephelometric assays in fresh serum samples. The levels of Lp(a) were significantly greater in CHD hypertensive patients (0.33 ?0.17 g/L) than in controls (0.18 ? 0.08 g/L) or patients with essential hypertension (0.20 ? 0.05 g/L). The levels of Lp(a) were increased more than 0.30 g/L in 46.6% of CHD hypertensive patiens, in 17.7% of hypertensive patiens and in 8.8% of controls. CHD hypertensive patients had also greater levels of total cholesterol, LDL-cholesterol and triglycerides than hypertensive patients and controls. HDL-cholesterol levels were significantly lower in CHD hypertensive patients. This study indicates that high Lp(a) levels can play a major role in the development of CHD in patients with essential hypertension. These findings suggest the great importance of identifying, among hypertensive patients, subjects with higher levels of Lp(a), who belong to a group with cardiovascular risk on the basis of their hypertension.

Sign in / Sign up

Export Citation Format

Share Document